ClinicalTrials.gg
RecruitingNCT06700304CAN-PRIMEUpdated May 31, 2025

CAN-PRIME: Precise Robotically Implanted Brain-Computer Interface for the Control of External Devices

An interventional study of N1 Implant and R1 Robot in Tetraplegia/Tetraparesis, Quadriplegia and Quadriplegia/Tetraplegia, sponsored by Neuralink Corp. Recruiting at 1 site in Canada. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-05-31.

Sponsored by Neuralink Corp · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Quadriplegia with a site in Canada — 5 open to participants now, 7 under way, 1 of them phase 3. Quadriplegia · Canada.

Planned enrollment
13th of 15
6 · median 25
Started
2024
with 1 other
No phase
9 of 19
3 open now
Registered
16th of 19
by date
Lead sponsor
1 of 19
Neuralink Corp

Among the 19 studies in Quadriplegia with a site in Canada, this one is the 13th largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2024, is one of 9 with no phase, and was the 16th registered.

Quadriplegia

224 studies on the registry are indexed under Quadriplegia; 77 are open to participants now.

Browse Quadriplegia studies →

Open to participants now

5 of the 19 studies in Quadriplegia with a site in Canada are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 57 Quadriplegia studies recruiting now, 17 (30%) set no upper age limit and 28 (49%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Quadriplegia with a site in Canada, or all of them as a file.
02

Study summary

The CAN-PRIME Study is to test the safety and functionality of Neuralink's N1 Implant and R1 Robot in people who have difficulty moving their arms and legs (tetraparesis or tetraplegia). The N1 Implant is a small, wireless device placed in the skull. It connects to tiny threads inserted into the brain by the R1 Robot, which is a machine designed to carefully place these threads. This study will help researchers learn how well the implant and robot work and if they are safe for use.

03

Conditions studied

  • Tetraplegia/Tetraparesis
  • Quadriplegia
  • Quadriplegia/Tetraplegia
  • Cervical Spinal Cord Injury
  • Amyotrophic Lateral Sclerosis (ALS)
  • Spinal Cord Injury (Quadraplegia)
  • Spinal Cord Injury

Keywords

  • brain computer interface
  • Neuralink N1 Implant
  • Neuralink
  • Robot
  • tetraparesis
  • tetraplegia
  • quadriplegia
  • ALS
  • spinal cord injury
  • Amyotrophic lateral sclerosis
  • chip
  • brain chip
  • External device control
  • Wireless implant
  • Neuroprosthetics
  • SCI
  • paralysis
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Severe quadriplegia (tetraplegia) due to spinal cord injury or amyotrophic lateral sclerosis (ALS) for at least 1 year without improvement, where quadriplegia is defined as having very limited or no hand, wrist, and arm movement and all levels below
  • ≥ 12 months.
  • Ability to communicate in English
  • Presence of a stable caregiver

Exclusion criteria

Exclusion Criteria:

  • Moderate to high risk for serious perioperative adverse events
  • Active implanted devices
  • Morbid obesity ( > 40)
  • History of poorly controlled seizures or epilepsy
  • History of poorly controlled diabetes
  • Requires magnetic resonance imaging (MRI) for any ongoing medical conditions
  • Acquired or hereditary
  • Use of smoking tobacco or other tobacco products
  • Psychiatric or psychological disorder
  • Brain MRI demonstrating hemorrhage, tumor, distorted or adverse anatomy.
  • Any condition which, in the opinion of the Investigator, would compromise your ability to safely participate in the study or undergo the implantation procedure
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (estimated)

Study arms

  • Other
    CAN-PRIME: Precise Robotically Implanted Brain-Computer Interface

    Open label

    Device: N1 Implant · Device: R1 Robot

Interventions

  • DeviceN1 Implant

    The N1 Implant is a type of implantable brain-computer interface.

  • DeviceR1 Robot

    The R1 Robot is a robotic electrode thread inserter that implants the N1 Implant.

06

What researchers measure

Primary outcomes

  1. The Rate of Device-Related Adverse Events (AE)

    Time frame: 12 months post-implant

  2. The Rate of Procedure-Related Adverse Events (AE)

    Time frame: 12 months post-implant

Secondary outcomes

  1. The Rate of Device-Related Adverse Events (AE)

    Time frame: Up to 36 months post-implant

  2. The Rate of Procedure-Related Adverse Events (AE)

    Time frame: Up to 36 months post-implant

  3. Change in Montreal Cognitive Assessment (MoCA) score during the Primary Study

    Time frame: From baseline to 3-, 6-, 9-, and 12-months post-implantation

  4. Change in Montreal Cognitive Assessment (MoCA) score during the Long-term Follow-up Phase

    Time frame: From baseline to 36-months post-implantation

  5. Change in Patient Health Questionnaire-9 (PHQ-9) score during the Primary Study

    Time frame: From baseline to 3-, 6-, 9-, and 12-months post-implantation

  6. Change in Patient Health Questionnaire-9 (PHQ-9) score during the Long-term Follow-up Phase

    Time frame: From baseline to 36-months post-implantation

  7. Change in Generalized Anxiety Disorder-7 (GAD-7) score during the Primary Study

    Time frame: From baseline to 3-, 6-, 9-, and 12-months post-implantation

  8. Change in Generalized Anxiety Disorder-7 (GAD-7) score during the Long-term Follow-up Phase

    Time frame: From baseline to 36-months post-implantation

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Nov 2027, 36 months after the start.

Of 97 interventional studies with no phase under Quadriplegia, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 309. This study's planned 36 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2024
First posted
Nov 21, 2024
StartActual
Nov 20, 2024
Primary completionEst.
Nov 30, 2027
CompletionEst.
Nov 30, 2030
Last update
May 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06700304
Lead sponsor
Neuralink Corp
Responsible party
Sponsor
First posted
Nov 21, 2024
Start date
Nov 20, 2024
Primary completion
Nov 30, 2027 (estimated)
Completion
Nov 30, 2030 (estimated)
Last update
May 31, 2025

Study contacts

Neuralink Clinical Team
Contact
clinical-team-ct@neuralink.com
(877) 398-4465

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion